Overview

Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with fibromyalgia syndrome.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Desvenlafaxine Succinate